Feb 12, 2026 04:30PM
Dec 17, 2025 08:30AM
Dec 17, 2025 08:30AM
Nov 17, 2025 09:26AM
Nov 13, 2025 04:30PM
Nov 3, 2025 11:04AM
Nov 3, 2025 08:30AM Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM
Oct 29, 2025 08:30AM
Aug 7, 2025 04:30PM
Jun 25, 2025 08:36AM
Jun 25, 2025 08:30AM
Jun 17, 2025 04:30PM Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Jun 2, 2025 08:31AM
Jun 2, 2025 08:30AM
Feb 13, 2025 04:30PM
Feb 5, 2025 08:32AM
Feb 5, 2025 08:30AM
Jan 10, 2025 08:30AM
Nov 7, 2024 04:20PM Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
Nov 5, 2024 08:30AM
Sep 23, 2024 08:31AM
Sep 23, 2024 08:30AM
Aug 13, 2024 04:21PM
Jun 11, 2024 04:20PM
May 23, 2024 08:30AM
Apr 9, 2024 08:30AM Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Apr 1, 2024 08:30AM
Apr 1, 2024 08:30AM
Feb 13, 2024 04:20PM
Dec 27, 2023 08:30AM
Dec 27, 2023 08:30AM
Dec 7, 2023 09:22AM
Dec 7, 2023 04:29AM Jefferies Upgrades VistaGen Therapeutics (VTGN) to Buy
Dec 4, 2023 07:08AM
Nov 9, 2023 04:30PM
Aug 10, 2023 04:22PM
Aug 10, 2023 04:21PM
Aug 10, 2023 09:01AM
Aug 10, 2023 09:00AM
Aug 7, 2023 08:34AM VistaGen Therapeutics (VTGN) Phase 3 PALISADE-2 Trial of Fasedienol Nasal Spray in Social Anxiety Disorder Meets Primary, Secondary Endpoints
Aug 7, 2023 08:30AM
Jun 28, 2023 04:25PM
Jun 21, 2023 08:30AM
Jun 1, 2023 08:32AM
Jun 1, 2023 08:30AM
May 30, 2023 04:15PM
Apr 19, 2023 08:31AM VistaGen Therapeutics (VTGN) Presents New Fasedienol (PH94B) Research
Apr 19, 2023 08:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All